<DOC>
	<DOCNO>NCT02505477</DOCNO>
	<brief_summary>The purpose study attempt treat cognitive negative symptom schizophrenia , nutritional supplement N-acetylcysteine ( NAC ) . Schizophrenia chronic mental disorder affect approximately 65 million people worldwide , cause significant disability suffering . Patients schizophrenia often hear voice persecutory delusion . Though recognizable feature illness , deficit closely link disability know cognitive deficit negative symptom . Cognitive ability refer ability perform mental task require focus attention , also include memory verbal skill . Negative symptom refer lack interest world , decrease social interaction . In study , investigator aim improve symptom deficit target glutamate system . Glutamate major excitatory neurotransmitter brain , regulation abnormal schizophrenia : glutamate level low receptor , high others . As well , free radical surround glutamate receptor also interfere proper function . N-acetylcystine ( NAC ) safe widely-available dietary supplement may restore glutamate correct level brain , may also help protect brain antioxidant damage . In study , patient schizophrenia randomly assign receive either NAC placebo 8 week . Brain level glutamate important antioxidant , glutathione , measure treatment , use neuroimaging technique know magnetic resonance spectroscopy . Cognitive negative symptom also assess , treatment . The investigator hypothesize glutamate glutathione normalize patient ' brain , negative cognitive symptom improve , .</brief_summary>
	<brief_title>Treatment Cognitive Negative Symptoms Schizophrenia With N-acetylcysteine</brief_title>
	<detailed_description>Schizophrenia severe mental illness associate hallucination delusion ( positive symptom ) , emotional withdrawal decrease expressivity ( negative symptom ) , problem memory , attention , social interaction ( cognitive impairment ) . Positive symptom , recognizable characteristic illness , treat effectively available antipsychotic medication . Cognitive deficit negative symptom , however , closely related functional outcome schizophrenia , yet , approve treatment type deficit ( 1,2 ) . One prominent theory propose deficit symptom arise dysfunctional receptor major excitatory neurotransmitter brain , glutamate ( 3 ) , two different way . First , believe decreased signal glutamate receptor inhibitory neuron lead excessive glutamate activity prefrontal cortex , result cognitive impairment ( 2 ) . This decrease signal glutamate receptor may result little glutamate present receptor mGlu2/3 subunit inhibitory neuron . In second mechanism , excessive oxidize specie surround glutamate receptor schizophrenia cause receptor hypofunction ( 2 ) . Glutathione , important protective molecule oxidative stress brain , protective . Importantly , glutathione find 52 % low medial prefrontal cortex schizophrenia patient compare control ( 4 ) . In rat , inhibition glutathione synthesis produce cognitive deficit , recent study show inverse correlation glutathione negative symptom patient ( 5,6 ) . Remarkably , agent affect glutamate glutathione : dietary supplement N-acetylcysteine , NAC . NAC safe widely available dietary supplement may able alter pathophysiology schizophrenia affect glutamate glutathione . Within glutamate system , NAC act inhibitory neuron restore inhibitory tone glutamatergic neuron frontal cortex ( 7 ) . A study publish 2012 show NAC normalized glutamate level cingulate cortex cocaine-dependent patient ( 8 ) . Remarkably , NAC also precursor glutathione , NAC administration increase serum glutathione concentration ( 9,10 ) . In one randomized , placebo-controlled study , NAC administration correlate improvement negative symptom schizophrenia patient ( 11 ) . We propose investigate mechanism putative therapeutic benefit NAC patient schizophrenia , explore impact negative symptom cognition . In study , use magnetic resonance spectroscopy ( MRS ) measure glutamate level prefrontal cortex , hypothesize NAC normalize , therefore reduce , level glutamate . We measure glutathione level MRS serum level , hypothesize NAC increase glutathione level brain systemically . We measure negative symptom , treatment NAC , hypothesize improvement NAC treatment group compare placebo , base finding literature . Finally , exploratory aim , measure performance MATRICS Consensus Cognitive Battery ( MCCB ) , NAC treatment , test effect NAC cognition schizophrenia . In 40 subject diagnosis schizophrenia schizoaffective disorder , conduct randomize , double-blind , placebo-controlled study NAC ( total daily dose 2400mg ) placebo 8-week period . - Specific Aim 1 : Compare glutamate bilateral dorsolateral prefrontal cortex NAC vs. placebo treatment use MRS Hypothesis 1 : Prefrontal glutamate concentration normalize ( reduce ) treatment NAC , treatment placebo . - Specific Aim 2 : Compare glutathione medial prefrontal cortex NAC vs. placebo treatment use MRS - Hypothesis 2a : Medial prefrontal cortical glutathione concentration improve ( increase ) treatment NAC , placebo - Hypothesis 2b : Serum glutathione level increase treatment NAC , placebo - Specific Aim 3 : Compare negative symptom , NAC vs. placebo treatment Hypothesis 3 : Negative symptom improve treatment NAC , placebo - Exploratory Aim : Assess performance MCCB treatment NAC vs. placebo References 1 . Green , M. F. &amp; Nuchterlein , K. H. Should Schizophrenia Be Treated Neurocognitive Disorder ? Schizophrenia bulletin 25 , 309-318 ( 1999 ) . 2 . Moghaddam , B . &amp; Javitt , D. From Revolution Evolution : The Glutamate Hypothesis Schizophrenia Implication Treatment . Neuropsychopharmacology 37 , 4-15 ( 2011 ) . 3 . Moghaddam , B . Targeting metabotropic glutamate receptor treatment cognitive symptom schizophrenia . Psychopharmacology ( Berl ) 174 , ( 2004 ) . 4 . Do , K. Q. et al . Schizophrenia : glutathione deficit cerebrospinal fluid prefrontal cortex vivo . European Journal Neuroscience 12 , 3721-3728 ( 2000 ) . 5 . Castagn√© , V. , Rougemont , M. , Cuenod , M. &amp; Do , K. Q . Low brain glutathione ascorbic acid associate dopamine uptake inhibition rat 's development induce long-term cognitive deficit : relevance schizophrenia . Neurobiology Disease 15 , 93-105 ( 2004 ) . 6 . Matsuzawa , D. et al . Negative Correlation Brain Glutathione Level Negative Symptoms Schizophrenia : A 3T 1H-MRS Study . PLoS ONE 3 , e1944 ( 2008 ) . 7 . Berk , M. , Malhi , G. S. , Gray , L. J . &amp; Dean , O. M. The promise N-acetylcysteine neuropsychiatry . Trends Pharmacological Sciences 34 , 168-178 ( 2013 ) .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<criteria>Meet DSM5 criterion schizophrenia schizoaffective disorder Must able provide inform consent participate research project Actively participate experimental drug trial ( ) either currently within past month Psychiatric hospitalization within previous three month Medical hospitalization acute medical problem within previous three month A great 50 % change dose antipsychotic medication within previous three month They meet DSM5 criterion substance use disorder within previous three month History neurological illness include stroke , epilepsy , loss consciousness 60 minute</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>schiozphrenia</keyword>
	<keyword>cognition</keyword>
	<keyword>negative symptom</keyword>
	<keyword>glutamate</keyword>
	<keyword>glutathione</keyword>
	<keyword>N-acetylcysteine</keyword>
</DOC>